Cargando…

Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI

PURPOSE: While [(18)F]-fluorodeoxyglucose ([(18)F]FDG) is the standard for positron emission tomography/computed tomography (PET/CT) imaging of oral squamous cell carcinoma (OSCC), diagnostic specificity is hampered by uptake in inflammatory cells such as neutrophils or macrophages. Recently, molecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Linz, Christian, Brands, Roman C., Kertels, Olivia, Dierks, Alexander, Brumberg, Joachim, Gerhard-Hartmann, Elena, Hartmann, Stefan, Schirbel, Andreas, Serfling, Sebastian, Zhi, Yingjun, Buck, Andreas K., Kübler, Alexander, Hohm, Julian, Lapa, Constantin, Kircher, Malte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484183/
https://www.ncbi.nlm.nih.gov/pubmed/34050405
http://dx.doi.org/10.1007/s00259-021-05422-z
_version_ 1784577265416273920
author Linz, Christian
Brands, Roman C.
Kertels, Olivia
Dierks, Alexander
Brumberg, Joachim
Gerhard-Hartmann, Elena
Hartmann, Stefan
Schirbel, Andreas
Serfling, Sebastian
Zhi, Yingjun
Buck, Andreas K.
Kübler, Alexander
Hohm, Julian
Lapa, Constantin
Kircher, Malte
author_facet Linz, Christian
Brands, Roman C.
Kertels, Olivia
Dierks, Alexander
Brumberg, Joachim
Gerhard-Hartmann, Elena
Hartmann, Stefan
Schirbel, Andreas
Serfling, Sebastian
Zhi, Yingjun
Buck, Andreas K.
Kübler, Alexander
Hohm, Julian
Lapa, Constantin
Kircher, Malte
author_sort Linz, Christian
collection PubMed
description PURPOSE: While [(18)F]-fluorodeoxyglucose ([(18)F]FDG) is the standard for positron emission tomography/computed tomography (PET/CT) imaging of oral squamous cell carcinoma (OSCC), diagnostic specificity is hampered by uptake in inflammatory cells such as neutrophils or macrophages. Recently, molecular imaging probes targeting fibroblast activation protein α (FAP), which is overexpressed in a variety of cancer-associated fibroblasts, have become available and might constitute a feasible alternative to FDG PET/CT. METHODS: Ten consecutive, treatment-naïve patients (8 males, 2 females; mean age, 62 ± 9 years) with biopsy-proven OSCC underwent both whole-body [(18)F]FDG and [(68)Ga]FAPI-04 (FAP-directed) PET/CT for primary staging prior to tumor resection and cervical lymph node dissection. Detection of the primary tumor, as well as the presence and number of lymph node and distant metastases was analysed. Intensity of tracer accumulation was assessed by means of maximum (SUV(max)) and peak (SUV(peak)) standardized uptake values. Histological work-up including immunohistochemical staining for FAP served as standard of reference. RESULTS: [(18)F]FDG and FAP-directed PET/CT detected all primary tumors with a SUV(max) of 25.5 ± 13.2 (FDG) and 20.5 ± 6.4 (FAP-directed) and a SUV(peak) of 16.1 ± 10.3 ([(18)F]FDG) and 13.8 ± 3.9 (FAP-directed), respectively. Regarding cervical lymph node metastases, FAP-directed PET/CT demonstrated comparable sensitivity (81.3% vs. 87.5%; P = 0.32) and specificity (93.3% vs. 81.3%; P = 0.16) to [(18)F]FDG PET/CT. FAP expression on the cell surface of cancer-associated fibroblasts in both primary lesions as well as lymph nodes metastases was confirmed in all samples. CONCLUSION: FAP-directed PET/CT in OSCC seems feasible. Future research to investigate its potential to improve patient staging is highly warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05422-z.
format Online
Article
Text
id pubmed-8484183
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-84841832021-10-08 Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI Linz, Christian Brands, Roman C. Kertels, Olivia Dierks, Alexander Brumberg, Joachim Gerhard-Hartmann, Elena Hartmann, Stefan Schirbel, Andreas Serfling, Sebastian Zhi, Yingjun Buck, Andreas K. Kübler, Alexander Hohm, Julian Lapa, Constantin Kircher, Malte Eur J Nucl Med Mol Imaging Original Article PURPOSE: While [(18)F]-fluorodeoxyglucose ([(18)F]FDG) is the standard for positron emission tomography/computed tomography (PET/CT) imaging of oral squamous cell carcinoma (OSCC), diagnostic specificity is hampered by uptake in inflammatory cells such as neutrophils or macrophages. Recently, molecular imaging probes targeting fibroblast activation protein α (FAP), which is overexpressed in a variety of cancer-associated fibroblasts, have become available and might constitute a feasible alternative to FDG PET/CT. METHODS: Ten consecutive, treatment-naïve patients (8 males, 2 females; mean age, 62 ± 9 years) with biopsy-proven OSCC underwent both whole-body [(18)F]FDG and [(68)Ga]FAPI-04 (FAP-directed) PET/CT for primary staging prior to tumor resection and cervical lymph node dissection. Detection of the primary tumor, as well as the presence and number of lymph node and distant metastases was analysed. Intensity of tracer accumulation was assessed by means of maximum (SUV(max)) and peak (SUV(peak)) standardized uptake values. Histological work-up including immunohistochemical staining for FAP served as standard of reference. RESULTS: [(18)F]FDG and FAP-directed PET/CT detected all primary tumors with a SUV(max) of 25.5 ± 13.2 (FDG) and 20.5 ± 6.4 (FAP-directed) and a SUV(peak) of 16.1 ± 10.3 ([(18)F]FDG) and 13.8 ± 3.9 (FAP-directed), respectively. Regarding cervical lymph node metastases, FAP-directed PET/CT demonstrated comparable sensitivity (81.3% vs. 87.5%; P = 0.32) and specificity (93.3% vs. 81.3%; P = 0.16) to [(18)F]FDG PET/CT. FAP expression on the cell surface of cancer-associated fibroblasts in both primary lesions as well as lymph nodes metastases was confirmed in all samples. CONCLUSION: FAP-directed PET/CT in OSCC seems feasible. Future research to investigate its potential to improve patient staging is highly warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05422-z. Springer Berlin Heidelberg 2021-05-29 2021 /pmc/articles/PMC8484183/ /pubmed/34050405 http://dx.doi.org/10.1007/s00259-021-05422-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Linz, Christian
Brands, Roman C.
Kertels, Olivia
Dierks, Alexander
Brumberg, Joachim
Gerhard-Hartmann, Elena
Hartmann, Stefan
Schirbel, Andreas
Serfling, Sebastian
Zhi, Yingjun
Buck, Andreas K.
Kübler, Alexander
Hohm, Julian
Lapa, Constantin
Kircher, Malte
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
title Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
title_full Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
title_fullStr Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
title_full_unstemmed Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
title_short Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
title_sort targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)f]fdg pet/ct and mri
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484183/
https://www.ncbi.nlm.nih.gov/pubmed/34050405
http://dx.doi.org/10.1007/s00259-021-05422-z
work_keys_str_mv AT linzchristian targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT brandsromanc targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT kertelsolivia targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT dierksalexander targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT brumbergjoachim targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT gerhardhartmannelena targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT hartmannstefan targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT schirbelandreas targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT serflingsebastian targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT zhiyingjun targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT buckandreask targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT kubleralexander targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT hohmjulian targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT lapaconstantin targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri
AT kirchermalte targetingfibroblastactivationproteininnewlydiagnosedsquamouscellcarcinomaoftheoralcavityinitialexperienceandcomparisonto18ffdgpetctandmri